Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In cross-sectional studies, elevated plasma homocysteine levels have been associated with poor cognition and dementia. Studies of newly diagnosed dementia are required in order to establish whether the elevated homocysteine levels precede the onset of dementia or result from dementia-related nutritional and vitamin deficiencies. METHODS: A total of 1092 subjects without dementia (667 women and 425 men; mean age, 76 years) from the Framingham Study constituted our study sample. We examined the relation of the plasma total homocysteine level measured at base line and that measured eight years earlier to the risk of newly diagnosed dementia on follow-up. We used multivariable proportional-hazards regression to adjust for age, sex, apolipoprotein E genotype, vascular risk factors other than homocysteine, and plasma levels of folate and vitamins B12 and B6. RESULTS: Over a median follow-up period of eight years, dementia developed in 111 subjects, including 83 given a diagnosis of Alzheimer's disease. The multivariable-adjusted relative risk of dementia was 1.4 (95 percent confidence interval, 1.1 to 1.9) for each increase of 1 SD in the log-transformed homocysteine value either at base line or eight years earlier. The relative risk of Alzheimer's disease was 1.8 (95 percent confidence interval, 1.3 to 2.5) per increase of 1 SD at base line and 1.6 (95 percent confidence interval, 1.2 to 2.1) per increase of 1 SD eight years before base line. With a plasma homocysteine level greater than 14 micromol per liter, the risk of Alzheimer's disease nearly doubled. CONCLUSIONS: An increased plasma homocysteine level is a strong, independent risk factor for the development of dementia and Alzheimer's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Adjudication for Alzheimer’s phenotypes was done by a committee41, comprising at least two neurologists and a neuropsychologist.”
From Clonal hematopoiesis is associated with protection from Alzheimer’s disease (2023) · cites this paper as [41]
In the citing paper
“Dementia diagnoses were made according to DSM‐IV criteria, based on longitudinal cognitive assessments, caregiver interviews, medical records, neuroimaging, and autopsy data when available.”
From Blood PCSK9 Impacts Alzheimer's Disease Risk in an APOE Genotype‐Dependent Manner: A Prospective Cohort Study (2026) · cites this paper as [18]
In the citing paper
“Overall, of the 19 selected cohort studies linking Hcy to the various cognitive outcomes, 12(63.2%) found the relationship in the hypothesized direction in the entire population that was studied and for most outcomes of interest [206,215,217,219,222-224,228,231,233-235]”
From Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis (2014) · cites this paper as [206]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Homocysteine and Atherothrombosis
Welch, G. N., & Loscalzo, J. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804093381507 · Cited by 1,997
Vitamin Status and Intake as Primary Determinants of Homocysteinemia in an Elderly Population
Selhub, J. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510220049033 · Cited by 1,972
Self-citationBrookmeyer, R., Gray, S., & Kawas, C. (1998) · American Journal of Public Health · doi:10.2105/ajph.88.9.1337 · Cited by 1,787
A Prospective Study of Plasma Homocyst(e)ine and Risk of Myocardial Infarction in US Physicians
Stampfer, M. J. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03490070059042 · Cited by 1,709
Brain Infarction and the Clinical Expression of Alzheimer Disease<subtitle>The Nun Study</subtitle>
Snowdon, D. A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340047031 · Cited by 1,590
Aging, energy, and oxidative stress in neurodegenerative diseases
Beal, M. F. (1995) · Annals of Neurology · doi:10.1002/ana.410380304 · Cited by 1,440
Research works printed but not linked: 3
- Berg L, 1988, Psychopharmacol Bull, 24, 637
- Levin ML, 1953, Acta Unio Int Contr Cancrum, 9, 531
- 1996, Fed Regist, 61, 8781
Cited by
Items 201–300 of 1,022
Fuso, A., Nicolia, V., Cavallaro, R. A., Ricceri, L., D'Anselmi, F., Coluccia, P., Calamandrei, G., & Scarpa, S. (2008) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2007.12.018 · Cited by 196
Other relevant components of nuts: phytosterols, folate and minerals
Segura, R., Javierre, C., Lizarraga, M. A., & Ros, E. (2006) · British Journal of Nutrition · doi:10.1017/bjn20061862 · Cited by 195
“2002) and an increased risk of development of Alzheimer disease (Seshadri et al. 2002).”
BackgroundInfluentialA Naphthalimide-Based Glyoxal Hydrazone for Selective Fluorescence Turn-On Sensing of Cys and Hcy
Wang, P., Liu, J., Lv, X., Liu, Y., Zhao, Y., & Guo, W. (2012) · Organic Letters · doi:10.1021/ol203123t · Cited by 195
Presenilin 1 gene silencing by S‐adenosylmethionine: a treatment for Alzheimer disease?
Scarpa, S., Fuso, A., D'Anselmi, F., & Cavallaro, R. A. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00277-1 · Cited by 194
Cognitive function in dialysis patients
Pereira, A. A., Weiner, D. E., Scott, T., & Sarnak, M. J. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.10.024 · Cited by 195
Epigenetic changes in the progression of Alzheimer's disease
Bradley-Whitman, M. A., & Lovell, M. A. (2013) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2013.08.005 · Cited by 193
“Additionally, alteration of sadenosylmethionine/homocysteine cycle has been suggested as a possible risk factor for AD (Seshadri et al., 2002) through modulation of PS1 expression (Fuso et al.”
BackgroundHan, B., & Wang, E. (2011) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2010.11.011 · Cited by 192
“Hcy s a risk factor for cardiovascular diseases and Alzheimer’s disease Seshadri et al., 2002).”
BackgroundVitamin B 12 status and rate of brain volume loss in community-dwelling elderly
Vogiatzoglou, A., Refsum, H., Johnston, C., Smith, S. M., Bradley, K. M., de Jager, C., Budge, M. M., & Smith, A. D. (2008) · Neurology · doi:10.1212/01.wnl.0000325581.26991.f2 · Cited by 192
Prolonged sleep duration as a marker of early neurodegeneration predicting incident dementia
Westwood, A. J., Beiser, A., Jain, N., Himali, J. J., DeCarli, C., Auerbach, S. H., Pase, M. P., & Seshadri, S. (2017) · Neurology · doi:10.1212/wnl.0000000000003732 · Cited by 192
“These covariates were chosen because they are among the strongest predictors of dementia in our sample.(12,13) Statistical models for TCBV and cognition included an additional adjustment for the time delay between the measurement of sleep duration and the outcome and age squared in the case of TCBV (given that associa…”
Self-citationCobalamin: a critical vitamin in the elderly
Wolters, M., Ströhle, A., & Hahn, A. (2004) · Preventive Medicine · doi:10.1016/j.ypmed.2004.04.047 · Cited by 130
Scientific Opinion on Dietary Reference Values for folate
EFSA Panel on Dietetic Products, N. A. A. (. (2014) · EFSA Journal · doi:10.2903/j.efsa.2014.3893 · Cited by 189
Wright, C. B., Paik, M. C., Brown, T. R., Stabler, S. P., Allen, R. H., Sacco, R. L., & DeCarli, C. (2005) · Stroke · doi:10.1161/01.str.0000165923.02318.22 · Cited by 189
Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease
Toth, C., Breithaupt, K., Ge, S., Duan, Y., Terris, J. M., Thiessen, A., Wiebe, S., Zochodne, D. W., & Suchowersky, O. (2010) · Annals of Neurology · doi:10.1002/ana.22021 · Cited by 188
“Although we hypothesize that prolonged L-dopa use indirectly leads to PN, other explanations for PN may include concurrent PNS neurodegeneration, problems with inadequate dietary intake in IPD patients contributing to MMA elevations, or genetic influences that may predispose to the development of cobalamin deficiency…”
BackgroundSeshadri, S. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9404 · Cited by 189
“A prospective evaluation of1092 dementia-freepersons belonging to the Framingham original cohort demonstrated that elevations in plasma tHcy over 8 yrs prior to the onset of clinical dementia predicted the subsequent development of AD, thereby establishing ‘temporali-ty’ [18].”
Self-citationHomocysteine Is a Protein Amino Acid in Humans
Jakubowski, H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200267200 · Cited by 190
Cardiovascular Risk Factors and Incident Alzheimer Disease: A Systematic Review of the Literature
Purnell, C., Gao, S., Callahan, C. M., & Hendrie, H. C. (2009) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318187541c · Cited by 189
“9 nmol/L increased risk,(51) whereas another from the Framingham study reported that low serum folate levels did not affect risk.(52) The third paper from WHICAP found that high levels of total folate intake (Z487.”
BackgroundCopper excess, zinc deficiency, and cognition loss in Alzheimer's disease
Brewer, G. J. (2012) · BioFactors · doi:10.1002/biof.1005 · Cited by 188
Ramos, M. I., Allen, L. H., Mungas, D. M., Jagust, W. J., Haan, M. N., Green, R., & Miller, J. W. (2005) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/82.6.1346 · Cited by 188
“Hyperhomocysteinemia is a risk factor for cerebrovascular disease (1) and has been shown to predict incident dementia in the Framingham study cohort (30).”
BackgroundThe prevalence and incidence of dementia: a systematic review and meta-analysis
Fiest, K. M., Jetté, N., Roberts, J. I., Maxwell, C. J., Smith, E. E., Black, S. E., Blaikie, L., Cohen, A., Day, L., Holroyd-Leduc, J., et al. (2016) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2016.18 · Cited by 188
“Seventeen studies reported on the incidence proportion of dementia,(10,138-140,142,146,148,150,151,155,157,159,165,167,175,176,183) with 10 eligible for inclusion in the meta-analysis of those aged 60+, 65+ or 70+ years.(139,140,148,150,157,159,165,175,176,183) All were from community settings.”
Can Dementia Be Prevented? Brain Aging in a Population-Based Context
Haan, M. N., & Wallace, R. (2004) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.25.101802.122951 · Cited by 188
Cerebrovascular lesions induce transient -amyloid deposition
Garcia-Alloza, M., Gregory, J., Kuchibhotla, K. V., Fine, S., Wei, Y., Ayata, C., Frosch, M. P., Greenberg, S. M., & Bacskai, B. J. (2011) · Brain · doi:10.1093/brain/awr300 · Cited by 187
“, 2004), plasma homocysteine (Seshadri et al., 2002), tobacco use (Ott et al.”
BackgroundYang, Z., Zhao, N., Sun, Y., Miao, F., Liu, Y., Liu, X., Zhang, Y., Ai, W., Song, G., Shen, X., et al. (2012) · Chemical Communications · doi:10.1039/c2cc00093h · Cited by 187
Chen, W., Luo, H., Liu, X., Foley, J. W., & Song, X. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.5b04333 · Cited by 186
Nutritional determinants of cognitive aging and dementia
Morris, M. C. (2012) · Proceedings of the Nutrition Society · doi:10.1017/s0029665111003296 · Cited by 186
Wright, A. J. A., Dainty, J. R., & Finglas, P. M. (2007) · British Journal of Nutrition · doi:10.1017/s0007114507777140 · Cited by 186
Amino acid catabolism in Alzheimer’s disease brain: Friend or foe?
Griffin, J. W. D., & Bradshaw, P. C. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/5472792 · Cited by 185
“Increased homocysteine levels in the plasma are a known risk factor for AD and other dementias [78].”
BackgroundHomocysteine and age-associated disorders
Ostrakhovitch, E. A., & Tabibzadeh, S. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2018.10.010 · Cited by 183
Evidence for defective retinoid transport and function in late onset Alzheimer's disease
Goodman, A. B., & Pardee, A. B. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437937100 · Cited by 184
Xiong, L., Zhao, Q., Chen, H., Wu, Y., Dong, Z., Zhou, Z., & Li, F. (2010) · Inorganic Chemistry · doi:10.1021/ic902266x · Cited by 182
Blood-Based Biomarkers of Alzheimer's Disease: Challenging but Feasible
Thambisetty, M., & Lovestone, S. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.84 · Cited by 182
Selenium and Alzheimer's Disease: A Systematic Review
Loef, M., Schrauzer, G. N., & Walach, H. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110414 · Cited by 181
“ious diseases including cognitive decline [252–254].”
McNulty, H., & Pentieva, K. (2004) · Proceedings of the Nutrition Society · doi:10.1079/pns2004383 · Cited by 181
“2004), certain cancers (Choi & Mason, 2000) and neuro-psychiatric conditions (Seshadri et al. 2002) are emerging.”
Zhang, Y., Li, Y., & Yan, X.-P. (2009) · Analytical Chemistry · doi:10.1021/ac900394e · Cited by 180
Hardman, R. J., Kennedy, G., Macpherson, H., Scholey, A. B., & Pipingas, A. (2016) · Frontiers in Nutrition · doi:10.3389/fnut.2016.00022 · Cited by 179
“A diet with the nutritional qualities of the MedDiet has been shown to reduce homocysteine levels, considered a risk factor for age-associated cognitive decline (58, 59).”
BackgroundGarlic reduces dementia and heart-disease risk
Borek, C. (2006) · The Journal of Nutrition · doi:10.1093/jn/136.3.810s · Cited by 176
Functional Vitamin B12 Deficiency and Determination of Holotranscobalamin in Populations at Risk
Herrmann, W., Obeid, R., Schorr, H., & Geisel, J. (2003) · Clinical Chemistry and Laboratory Medicine · doi:10.1515/cclm.2003.227 · Cited by 175
Seshadri, S., Wolf, P. A., Beiser, A. S., Selhub, J., Au, R., Jacques, P. F., Yoshita, M., Rosenberg, I. H., D’Agostino, R. B., & DeCarli, C. (2008) · Archives of Neurology · doi:10.1001/archneur.65.5.642 · Cited by 176
“E LEVATED PLASMA TOTAL HOmocysteine (tHcy) levels have been associated with an increased risk of clinical stroke,(1) dementia, and Alzheimer disease.(2) The mechanisms underlying the association with clinical dementia are uncertain and may involve both vascular and neuronal pathways.”
BackgroundSelf-citationGenetic polymorphisms and folate status
Hiraoka, M., & Kagawa, Y. (2017) · Congenital Anomalies · doi:10.1111/cga.12232 · Cited by 175
“1995), cognitive dysfunction (Seshadri et al. 2002), and depression (Bottiglieri 2005).”
BackgroundAntioxidant and Cell‐Signaling Functions of Hydrogen Sulfide in the Central Nervous System
Shefa, U., Kim, M.-S., Jeong, N. Y., & Jung, J. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/1873962 · Cited by 175
“Others with neurological diseases, such as AD, dementia and schizophrenia patients, also show increased homocysteine levels [139].”
BackgroundXiong, K., Huo, F., Chao, J., Zhang, Y., & Yin, C. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.8b04485 · Cited by 175
Changing demography and the challenge of dementia in India
Ravindranath, V., & Sundarakumar, J. S. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00565-x · Cited by 172
DNA methylation, a hand behind neurodegenerative diseases
Lu, H., Liu, X., Deng, Y., & Qing, H. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00085 · Cited by 174
Plasma biomarkers for mild cognitive impairment and Alzheimer's disease
Song, F., Poljak, A., Smythe, G. A., & Sachdev, P. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.05.003 · Cited by 173
“High plasma homocysteine over 14 μmol/L doubled the risk of AD in an eight year longitudinal study (Seshadri et al., 2002).”
BackgroundStanger, O., Fowler, B., Piertzik, K., Huemer, M., Haschke-Becher, E., Semmler, A., Lorenzl, S., & Linnebank, M. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.75 · Cited by 172
“Otherwise apparently healthy people with folate or vitamin B12 deficiency are at elevated risk to develop cognitive impairment and dementia [131,143,145-151].”
BackgroundInfluentialPlasma homocysteine levels and risk of Alzheimer disease
Luchsinger, J. A., Tang, M. X., Shea, S., Miller, J., Green, R., & Mayeux, R. (2004) · Neurology · doi:10.1212/01.wnl.0000129504.60409.88 · Cited by 171
Sharma, P., Senthilkumar, R., Brahmachari, V., Sundaramoorthy, E., Mahajan, A., Sharma, A., & Sengupta, S. (2006) · Lipids in Health and Disease · doi:10.1186/1476-511x-5-1 · Cited by 171
Hyperhomocysteinaemia and vascular injury: advances in mechanisms and drug targets
Fu, Y., Wang, X., & Kong, W. (2018) · British Journal of Pharmacology · doi:10.1111/bph.13988 · Cited by 170
“Under normal conditions, the concentration of homocysteine ranges from 5 to 10 μM in human plasma but does not exceed 15 μM (Seshadri et al., 2002).”
BackgroundFluorescent silver nanoclusters stabilized by DNA scaffolds
Yuan, Z., Chen, Y.-C., Li, H.-W., & Chang, H.-T. (2014) · Chemical Communications · doi:10.1039/c4cc02981j · Cited by 169
Phytochemicals and Dietary Fiber Components in Rye Varieties in the HEALTHGRAIN Diversity Screen
Nyström, L., Lampi, A.-M., Andersson, A. A. M., Kamal-Eldin, A., Gebruers, K., Courtin, C. M., Delcour, J. A., Li, L., Ward, J. L., Fraś, A., et al. (2008) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf801065r · Cited by 170
Clonal hematopoiesis is associated with protection from Alzheimer’s disease
Bouzid, H., Belk, J. A., Jan, M., Qi, Y., Sarnowski, C., Wirth, S., Ma, L., Chrostek, M. R., Ahmad, H., Nachun, D., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02397-2 · Cited by 169
Self-citationDual emission channels for sensitive discrimination of Cys/Hcy and GSH in plasma and cells
Zhang, Y., Shao, X., Wang, Y., Pan, F., Kang, R., Peng, F., Huang, Z., Zhang, W., & Zhao, W. (2015) · Chemical Communications · doi:10.1039/c4cc08687b · Cited by 169
Zhang, Y., Tang, Z.-H., Ren, Z., Qu, S.-L., Liu, M.-H., Liu, L.-S., & Jiang, Z.-S. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01215-12 · Cited by 168
Hyperhomocysteinemia and Thrombosis: An Overview
Eldibany, M. M., & Caprini, J. A. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-872-hatao · Cited by 171
Cerebral Vascular Dysfunction Mediated by Superoxide in Hyperhomocysteinemic Mice
Dayal, S., Arning, E., Bottiglieri, T., Böger, R. H., Sigmund, C. D., Faraci, F. M., & Lentz, S. R. (2004) · Stroke · doi:10.1161/01.str.0000131749.81508.18 · Cited by 168
Mulay, S. V., Kim, Y., Choi, M., Lee, D. Y., Choi, J., Lee, Y., Jon, S., & Churchill, D. G. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.7b04375 · Cited by 166
Yin, G., Gan, Y., Jiang, H., Yu, T., Liu, M., Zhang, Y., Li, H., Yin, P., & Yao, S. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c01945 · Cited by 167
Amarnath, K. (2003) · Talanta · doi:10.1016/s0039-9140(03)00232-7 · Cited by 164
Heart failure and Alzheimer′s disease
Cermakova, P., Eriksdotter, M., Lund, L. H., Winblad, B., Religa, P., & Religa, D. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12287 · Cited by 163
Walker, J. G., Batterham, P. J., Mackinnon, A. J., Jorm, A. F., Hickie, I., Fenech, M., Kljakovic, M., Crisp, D., & Christensen, H. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.007799 · Cited by 165
“The first is by lowering homocysteine concentrations (8–10), whereas the second purports that supplementary FA and vitamin B-12 may operate by reducing vascular and other metabolic risk factors (9).”
Tu, W., Lei, J., Wang, P., & Ju, H. (2011) · Chemistry – A European Journal · doi:10.1002/chem.201100577 · Cited by 165
Folates and aging: Role in mild cognitive impairment, dementia and depression
Araújo, J. R., Martel, F., Borges, N., Araújo, J. M., & Keating, E. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.04.005 · Cited by 163
Endoplasmic reticulum stress in disease: mechanisms and therapeutic opportunities
Hosoi, T., & Ozawa, K. (2010) · Clinical Science · doi:10.1042/cs20080680 · Cited by 164
Hyperhomocysteinemia and Alzheimer's disease: A systematic review
Van Dam, F., & Van Gool, W. A. (2009) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2008.03.009 · Cited by 162
“, 2005) and 7 years in another study (Seshadri et al., 2002).”
BackgroundMethodInfluentialKamat, P. K., Kyles, P., Kalani, A., & Tyagi, N. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9212-4 · Cited by 163
“An elevated plasma homocysteine level, known as hyperhomocystemia (HHcy), was found to be associated with an increased risk factor for strokes [1], vascular dementia, and Alzheimer’s disease (AD) [2, 3].”
BackgroundMavros, Y., Gates, N., Wilson, G. C., Jain, N., Meiklejohn, J., Brodaty, H., Wen, W., Singh, N., Baune, B. T., Suo, C., et al. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14542 · Cited by 162
Blaise, S. A., Nédélec, E., Schroeder, H., Alberto, J.-M., Bossenmeyer-Pourié, C., Guéant, J.-L., & Daval, J.-L. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060339 · Cited by 162
The neurology of folic acid deficiency
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-7020-4087-0.00061-9 · Cited by 163
Chan, K., Chui, S. H., Wong, D. Y. L., Ha, W. Y., Chan, C. L., & Wong, R. N. S. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.06.010 · Cited by 161
Disease‐modifying therapies in Alzheimer's disease
Salloway, S., Mintzer, J., Weiner, M. F., & Cummings, J. L. (2008) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.10.001 · Cited by 161
“[91] Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D’Agostino RB, et al.”
Homocysteine: Its Possible Emerging Role in At-Risk Population Groups
Azzini, E., Ruggeri, S., & Polito, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041421 · Cited by 161
“[162] in an 8 year follow-up study on 1092 subjects without”
BackgroundPathogenesis of cerebral amyloid angiopathy
Rensink, A. A. M., de Waal, R. M. W., Kremer, B., & Verbeek, M. M. (2003) · Brain Research Reviews · doi:10.1016/j.brainresrev.2003.08.001 · Cited by 159
Olteanu, H., Munson, T., & Banerjee, R. (2002) · Biochemistry · doi:10.1021/bi020536s · Cited by 160
Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved
Thong, B. K. S., Ima-Nirwana, S., & Chin, K.-Y. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16091571 · Cited by 159
Kalback, W., Esh, C., Castaño, E. M., Rahman, A., Kokjohn, T., Luehrs, D. C., Sue, L., Cisneros, R., Gerber, F., Richardson, C., et al. (2004) · Neurological Research · doi:10.1179/016164104225017668 · Cited by 160
Corrada, M. M., Kawas, C. H., Hallfrisch, J., Muller, D., & Brookmeyer, R. (2005) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2005.06.001 · Cited by 159
“One showed increased levels of plasma omocysteine as a strong risk factor for the development of D [8], whereas another smaller study [7] found that subects with low serum levels of folate or vitamin B12 had ouble the risk of an AD diagnosis 3 years later.”
BackgroundResultInfluentialRogers, J. D., Sanchez-Saffon, A., Frol, A. B., & Diaz-Arrastia, R. (2003) · Archives of Neurology · doi:10.1001/archneur.60.1.59 · Cited by 160
Mooijaart, S. P., Gussekloo, J., Frölich, M., Jolles, J., Stott, D. J., Westendorp, R. G., & de Craen, A. J. (2005) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/82.4.866 · Cited by 159
“Increased plasma concentrations of homocysteine have been associated with an increased prevalence of poor cognitive function (12) and an increased risk of development of dementia and Alzheimer disease (13).”
BackgroundThe role of hyperhomocysteinemia and B-vitamin deficiency in neurological and psychiatric diseases
Obeid, R., McCaddon, A., & Herrmann, W. (2007) · Clinical Chemical Laboratory Medicine · doi:10.1515/cclm.2007.356 · Cited by 159
“The northern Manhattan community had higher baseline tHcy levels, included more subjects with diabetes, were older than subjects in the Framingham study (38) and included several ethnic groups (46).”
BackgroundInfluentialSelley, M. L. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00007-1 · Cited by 158
Homocysteine induces tau phosphorylation by inactivating protein phosphatase 2A in rat hippocampus
Zhang, C.-E., Tian, Q., Wei, W., Peng, J.-H., Liu, G.-P., Zhou, X.-W., Wang, Q., Wang, D.-W., & Wang, J.-Z. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.015 · Cited by 159
Kidd, P. M. (2008) · PubMed · Cited by 203
Poly, C., Massaro, J. M., Seshadri, S., Wolf, P. A., Cho, E., Krall, E., Jacques, P. F., & Au, R. (2011) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.008938 · Cited by 159
“High homocysteine concentrations have been shown to be related to both cognitive impairments in nondemented samples and an increased risk of AD (14, 15).”
BackgroundSelf-citationLiu, Y., Yu, Y., Lam, J. W. Y., Hong, Y., Faisal, M., Yuan, W. Z., & Tang, B. Z. (2010) · Chemistry – A European Journal · doi:10.1002/chem.200902505 · Cited by 158
Specific Hg2+-mediated perylene bisimide aggregation for highly sensitive detection of cysteine
Ruan, Y.-B., Li, A.-F., Zhao, J.-S., Shen, J.-S., & Jiang, Y.-B. (2010) · Chemical Communications · doi:10.1039/c0cc00630k · Cited by 158
Homocysteine and brain atrophy
Sachdev, P. S. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.06.026 · Cited by 158
Cognitive function and hypertension
Birns, J., & Kalra, L. (2009) · Journal of Human Hypertension · doi:10.1038/jhh.2008.80 · Cited by 157
Dietary Patterns and Survival of Older Adults
Anderson, A. L., Harris, T. B., Tylavsky, F. A., Perry, S. E., Houston, D. K., Hue, T. F., Strotmeyer, E. S., & Sahyoun, N. R. (2011) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2010.10.012 · Cited by 153
Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither?
Zhuo, J.-M., Wang, H., & Praticò, D. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.05.003 · Cited by 155
Neuroenhancement with Vitamin B12—Underestimated Neurological Significance
Gröber, U., Kisters, K., & Schmidt, J. (2013) · Nutrients · doi:10.3390/nu5125031 · Cited by 183
“In the major Framingham study, the risk of Alzheimer’s disease was nearly doubled at homocysteine levels >14 μmol/L [39].”
BackgroundDementia Prevention: Methodological Explanations for Inconsistent Results
Coley, N., Andrieu, S., Gardette, V., Gillette-Guyonnet, S., Sanz, C., Vellas, B., & Grand, A. (2008) · Epidemiologic Reviews · doi:10.1093/epirev/mxn010 · Cited by 154
Ullah, R., Khan, M., Shah, S. A., Saeed, K. M., & Kim, M. O. (2019) · Nutrients · doi:10.3390/nu11061195 · Cited by 169
“Furthermore, hyperhomocysteinemia, homocysteine [51,52] and apolipoprotein E4 (ApoE4) [53] are strong factors involved in mitochondrial dysfunction leading to AD development.”
BackgroundLv, H., Yang, X., Zhong, Y., Guo, Y., Li, Z., & Li, H. (2014) · Analytical Chemistry · doi:10.1021/ac4038027 · Cited by 160
Nutrient patterns and brain biomarkers of Alzheimer's disease in cognitively normal individuals
Berti, V., Murray, J., Davies, M., Spector, N., Tsui, W. H., Li, Y., Williams, S., Pirraglia, E., Vallabhajosula, S., McHugh, P., et al. (2015) · The Journal of nutrition, health and aging · doi:10.1007/s12603-014-0534-0 · Cited by 152
“6) Blood pressure (mm/Hg), mean (SD) Systolic 119(14) Diastolic 72(8) Glucose (mg/dl) 78(12) Cholesterol (mg/dl) 197(37) HDL (mg/dl) 62(18) LDL (mg/dl) 117(32) Triglycerides (mg/dl) 89(39) Homocysteine (micromol/l) 10(3) Neuropsychological tests, mean (SD) Mini Mental State Exam 29(1) Digit symbol substitution 63(10)…”
Francioso, A., Conrado, A. B., Mosca, L., & Fontana, M. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/8294158 · Cited by 172
“Mild hyperhomocysteinemia is a common clinical condition associated with an increased risk for cardiovascular and neurodegenerative diseases [229, 230].”
BackgroundPlasma total homocysteine and memory in the elderly: The Hordaland Homocysteine study
Nurk, E., Refsum, H., Tell, G. S., Engedal, K., Vollset, S. E., Ueland, P. M., Nygaard, H. A., & Smith, A. D. (2005) · Annals of Neurology · doi:10.1002/ana.20645 · Cited by 153
“In contrast, in most studies conducted among people with an age range similar our cohort, tHcy is a risk factor for impaired cognition, dementia, or both.(6,11,16,19,21,23,58) We found that low folate status was associated with memory deficit and lower KOLT score.”
BackgroundResultRoberts, W. L. (2004) · Circulation · doi:10.1161/01.cir.0000148986.52696.07 · Cited by 152
Alzheimer’s disease, cerebrovascular disease, and the β-amyloid cascade
Honjo, K., Black, S. E., & Verhoeff, N. P. L. G. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100015547 · Cited by 152
Impact of chronic Helicobacter pylori infection on Alzheimer's disease: preliminary results
Baudron, C. R., Krolak‐Salmon, P., Quadrio, I., Mégraud, F., & Salles, N. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.10.021 · Cited by 170
Highly selective fluorescent sensor for homocysteine and cysteine
Kim, T.-K., Lee, D.-N., & Kim, H.-J. (2008) · Tetrahedron Letters · doi:10.1016/j.tetlet.2008.06.003 · Cited by 152
Effect of l-dopa on plasma homocysteine in PD patients: Relationship to B-vitamin status
Miller, J. W., Selhub, J., Nadeau, M. R., Thomas, C. A., Feldman, R. G., & Wolf, P. A. (2003) · Neurology · doi:10.1212/01.wnl.0000055899.24594.8e · Cited by 152
Self-citation
Metadata
- Authors
- Seshadri, S., Beiser, A., Selhub, J., Jacques, P. F., Rosenberg, I. H., D'Agostino, R. B., Wilson, P. W. F., & Wolf, P. A.
- Affiliations
- Boston University (US)
- Tufts University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-02-14
- Volume
- 346
- Issue
- 7
- Pages
- 476-483
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2052588755
- Cited by
- 3,237
- References
- 55
- Citations by year
- 2026: 49 · 2025: 61 · 2024: 82 · 2023: 79 · 2022: 90 · 2021: 102 · 2020: 91 · 2019: 133 · 2018: 132 · 2017: 138 · 2016: 138 · 2015: 149 · 2014: 174 · 2013: 154 · 2012: 155
- FWCI
- 111.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01hc038038-022)
- National Institute on Aging (5R01 AG 08122-11, 5R01-AG16495-02, R01AG016495, R01AG008122)
- National Heart, Lung, and Blood Institute (N01-HC-38038)
- National Institute of Neurological Disorders and Stroke (5R01 NS 17950-19, R01NS017950)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Folate and B Vitamins Research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- plasma homocysteine, dementia, Alzheimer's disease, risk factors, newly diagnosed dementia, folic acid, vitamin B12, vitamin B6, apolipoprotein E, Framingham Heart Study, cognitive decline
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Dementia, Female, Homocysteine, Humans, Male, Risk Factors, Cohort Studies, Confounding Factors, Epidemiologic, Multivariate Analysis, Proportional Hazards Models, Hyperhomocysteinemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.